Oncimmune (LON:ONC) Shares Down 5.6% – Here’s Why

Oncimmune Holdings plc (LON:ONC)’s share price was down 5.6% on Tuesday . The company traded as low as GBX 1.70 ($0.02) and last traded at GBX 1.70 ($0.02). Approximately 202,924 shares changed hands during trading, a decline of 67% from the average daily volume of 619,508 shares. The stock had previously closed at GBX 1.80 ($0.02).

Oncimmune Stock Down 3.3 %

The company has a quick ratio of 0.63, a current ratio of 1.14 and a debt-to-equity ratio of -412.06. The company has a market cap of £1.97 million, a PE ratio of 0.20 and a beta of 1.19. The company’s fifty day moving average is GBX 9.98 and its 200-day moving average is GBX 14.12.

Oncimmune (LON:ONC) last released its quarterly earnings results on Monday, February 10th. The company reported GBX (4.72) (($0.06)) earnings per share (EPS) for the quarter. Oncimmune had a negative return on equity of 2,277.74% and a net margin of 581.63%.

Oncimmune Company Profile

Oncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, an immunodiagnostic blood test for detecting and identifying lung cancer; ImmunoINSIGHTS that enables life science organizations to optimize drug development and delivery; SeroTag discovery arrays for discovering and validating biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel.